Status: Not yet recruiting
A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment
This is a Phase I trial designed to evaluate the impact of renal impairment on the efficacy and safety of the drug by comparing pharmacokinetic (PK) parameters and pharmacodynamic (PD) markers after a single subcutaneous injection of RG002C0106 between trial participants with normal renal function and those with mild to moderate renal impairment.
Participants needed: 24
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.Updated: Mar 3, 2026
Eligibility criteria
Have been fully informed about the study, volunteered to participate, and provid... [+3]
At screening, chest radiography demonstrates clinically significant abnormalitie... [+9]